Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

China Halts Work by Team on Gene-Edited Babies

By Marilynn Marchione, AP Chief Medical Writer | November 29, 2018

HONG KONG (AP) — China’s government ordered a halt Thursday to work by a medical team that claimed to have helped make the world’s first gene-edited babies, as a group of leading scientists declared that it’s still too soon to try to make permanent changes to DNA that can be inherited by future generations.

Chinese Vice Minister of Science and Technology Xu Nanping told state broadcaster CCTV that his ministry is strongly opposed to the efforts that reportedly produced twin girls born earlier this month. Xu called the team’s actions illegal and unacceptable and said an investigation had been ordered, but made no mention of specific actions taken.

Researcher He Jiankui claims to have altered the DNA of the twins to try to make them resistant to infection with the AIDS virus. Mainstream scientists have condemned the experiment, and universities and government groups are investigating.

He’s experiment “crossed the line of morality and ethics adhered to by the academic community and was shocking and unacceptable,” Xu said.

A group of leading scientists gathered in Hong Kong this week for an international conference on gene editing, the ability to rewrite the code of life to try to correct or prevent diseases.

Although the science holds promise for helping people already born and studies testing that are underway, a statement issued Thursday by the 14-member conference leaders says it’s irresponsible to try it on eggs, sperm or embryos except in lab research because not enough is known yet about its risks or safety.

The conference was rocked by the Chinese researcher’s claim to have helped make the world’s first gene-edited babies. Conference leaders called for an independent investigation of the claim by He, who spoke to the group Wednesday as international criticism of his claim mounted.

There is no independent confirmation of what He says he did. He was scheduled to speak again at the conference on Thursday, but he left Hong Kong and through a spokesman sent a statement saying “I will remain in China, my home country, and cooperate fully with all inquiries about my work. My raw data will be made available for third party review.”

Several prominent scientists said the case showed a failure of the field to police itself and the need for stricter principles or regulations.

“It’s not unreasonable to expect the scientific community” to follow guidelines, said David Baltimore, a Nobel laureate from California Institute of Technology who led the panel.

There already are some rules that should have prevented what He says he did, said Alta Charo, a University of Wisconsin lawyer and bioethicist and a conference organizer.

“I think the failure was his, not the scientific community,” Charo said.

Gene editing for reproductive purposes might be considered in the future “but only when there is compelling medical need,” with clear understanding of risks and benefits, and certain other conditions, said Dr. Victor Dzau, president of the U.S. National Academy of Medicine, one of the conference sponsors.

“Not following these guidelines would be an irresponsible act,” he added.

Other sponsors of the three-day conference are the Academy of Sciences of Hong Kong, the Royal Society of the United Kingdom and the U.S. National Academy of Sciences and U.S. National Academy Sciences.

___

The Associated Press Health & Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

(AP Photo/Mark Schiefelbein)

Related Articles Read More >

Plastic Ingenuity Germany Facility (1)
Plastic Ingenuity expands operations into Europe with Spezi-Pack acquisition
BioDuro_logo_color
BioDuro, Cenra launch joint venture for API manufacturing
Novo Nordisk
Novo Nordisk announces $507M GLP-1 manufacturing expansion in Ireland
This is the logo of Novartis.
Novartis to build new radioligand therapy manufacturing site in Texas
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE